Ummuhan Abdulrezzak1, Ahmet Tutus2, Ilknur Isik3, Yurdagul Kurt2, Mustafa Kula2. 1. Department of Nuclear Medicine, Erciyes University, School of Medicine, Kayseri, Turkey - ummuhan@erciyes.edu.tr. 2. Department of Nuclear Medicine, Erciyes University, School of Medicine, Kayseri, Turkey. 3. Department of Nuclear Medicine, Dumlupınar University, School of Medicine, Kütahya, Turkey.
Abstract
BACKGROUND: The aim of this paper was to compare the results of postoperative I-131 remnant ablation therapy using a quantitative data in the low activity (1110 MBq) and standard dose (3700 MBq). METHODS: The study included two groups of patients with low risk differentiated thyroid cancer (DTC): Group L (low dose group) included 54 patients who were treated with 1110 MBq I-131 and Group S (standard dose group) included 61 patients treated with 3700 MBq. The postoperative thyroid remnants were assessed with the pretreatment thyroid uptake test (PTUT) and the whole body scans (WBS) were performed in the 7th day after the ablation treatment. We obtained the average count per pixel from the standard region of interest analysis of the thyroid bed (Tavc), liver (Lavc), thigh (Thavc) and whole body (WBkc). At the sixth month after the treatment, WBS were performed to 106 patients (45 patients from Group L and 61 patients from Group S) to evaluate the success of ablation treatment. RESULTS: A significant difference in PTUT and Tavc was not found between the two groups (P>0.05). However, Lavc, Thavc and WBkc were significantly higher in Group S compared with Group L (P<0.001). Although the percentage of ablation was higher in Group S (49 of 61 patients, 80.3% versus 34 of 45 patients, 75.6%), the statistical difference was not significant (P>0.05). CONCLUSIONS: In low risk DTC patients, low dose radioactive iodine can ablate thyroid remnants as effectively as a higher dose with less radiation exposure to other non-target organs and the whole body.
BACKGROUND: The aim of this paper was to compare the results of postoperative I-131 remnant ablation therapy using a quantitative data in the low activity (1110 MBq) and standard dose (3700 MBq). METHODS: The study included two groups of patients with low risk differentiated thyroid cancer (DTC): Group L (low dose group) included 54 patients who were treated with 1110 MBq I-131 and Group S (standard dose group) included 61 patients treated with 3700 MBq. The postoperative thyroid remnants were assessed with the pretreatment thyroid uptake test (PTUT) and the whole body scans (WBS) were performed in the 7th day after the ablation treatment. We obtained the average count per pixel from the standard region of interest analysis of the thyroid bed (Tavc), liver (Lavc), thigh (Thavc) and whole body (WBkc). At the sixth month after the treatment, WBS were performed to 106 patients (45 patients from Group L and 61 patients from Group S) to evaluate the success of ablation treatment. RESULTS: A significant difference in PTUT and Tavc was not found between the two groups (P>0.05). However, Lavc, Thavc and WBkc were significantly higher in Group S compared with Group L (P<0.001). Although the percentage of ablation was higher in Group S (49 of 61 patients, 80.3% versus 34 of 45 patients, 75.6%), the statistical difference was not significant (P>0.05). CONCLUSIONS: In low risk DTCpatients, low dose radioactive iodine can ablate thyroid remnants as effectively as a higher dose with less radiation exposure to other non-target organs and the whole body.
Authors: Elizabeth J de Koster; Taban Sulaiman; Jaap F Hamming; Abbey Schepers; Marieke Snel; Floris H P van Velden; Lioe-Fee de Geus-Oei; Dennis Vriens Journal: Diagnostics (Basel) Date: 2021-03-19